Clinical trials
Observational Recurrence trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2010 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Recruiting | 8 |
| Unknown status | 7 |
| Not yet recruiting | 2 |
| Enrolling by invitation | 2 |
| Terminated | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 3 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 3 |
| IRCCS San Raffaele | 3 |
| Fondazione Italiana Linfomi - ETS | 2 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 2 |
| AGO Study Group | 1 |
| AbbVie | 1 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Andrés José Maria Ferreri | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 40 |
| Carcinoma, Hepatocellular | 3 |
| Ovarian Neoplasms | 3 |
| Disease | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Liver Neoplasms | 2 |
| Lymphoma, Mantle-Cell | 2 |
| Multiple Myeloma | 2 |
| Multiple Sclerosis | 2 |
| Neoplasms | 2 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.